mdma
-
antidepressants, depression, Drugs, FDA rejection, functional unblinding, Lykos, mdma, media coverage, neuroscience, psilocybin, psychedelic medicine, Psychiatry, Psychology, PTSD, science communication, Stress, treatment-resistant depressionPsychedelic Media Coverage Outpaced Evidence (2017–2024)
Psychedelic-assisted therapy has been one of the most-covered mental-health stories of the…
-
adverse events, antidepressants, British Journal of Psychiatry, clinical trial, depression, difficult-to-treat depression, Editor Eimear Foley, feasibility, major depressive disorder, mdma, MDMA-assisted psychotherapy, open label study, placebo, proof-of-principle, psychedelics, psychotherapy, randomised controlled trial, remission, Safety, Suicidal Ideation, tolerability, topicalMDMA-assisted therapy for depression: a promising but early first step
MDMA was first made in 1912 as an accidental byproduct of a…
-
depression, functional unblinding, MAPS, mdma, MDMA-assisted therapy, Phase 3 trial, psilocybin, psychedelics, PTSD, treatment-resistant depressionPsilocybin for Depression, MDMA for PTSD: What Phase 3 Trials Show
Research Highlights Media coverage of psychedelics is measurably more positive than coverage…
